Martec/Egis Pharmaceuticals partnership
Martec agreement with Budapest, Hungary-based firm provides the U.S. company with all pharmaceutical compounds developed by Egis over the next 13 years. Martec will have the exclusive right to market these compounds in the U.S., Canada and Mexico. Martec also will aid Egis in establishing a new R&D facility. Egis generates annual revenues of $ 175 mil., according to Martec.
You may also be interested in...
Grant from Department of Commerce Market Development Cooperator Program funds project for four years. In addition to grant, the project partners – UNPA, National Animal Supplement Council, Eurofins Scientific testing company and China Inspections and Testing Society – get DoC assistance.
Avadim Health argues National Advertising Division expects substantiation for its homeopathic topical claims at the same level FDA requires for NDAs. NAD also said although FTC’s competent, reliable scientific evidence standard is “flexible” to some degree, pain claims are held to a more rigid standard.
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.